Skip to content

Effects of Remazolam on hemodynamics, tracheal intubation stress and agitation during recovery from general anesthesia in patients with OSAHS

Effects of Remazolam on hemodynamics, tracheal intubation stress and agitation during recovery from general anesthesia in patients with OSAHS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088350
Enrollment
Unknown
Registered
2024-08-16
Start date
2024-08-18
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive sleep apnea hypopnea disorder syndrome

Interventions

Group R:Anesthesia induction: intravenous remazolam 0.25mg/kg
Anesthesia maintenance: Remazolam was injected with 0.3 ~ 0.6mg/kg/h
Group B:Induction of anesthesia: propofol 2.5mg/kg
Anesthetic maintenance: pump propofol 3 ~ 6mg/kg/h
Group E:Anesthesia induction: intravenous etomidate 0.25mg/kg
Anesthesia maintenance: etomidate 0.3 ~ 0.6mg/kg/h

Sponsors

Lu'an Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: OSAHS patients with ASA grade I to III, male or female, aged 18 to 64 years old, were selected to undergo UPPP surgery in our hospital

Exclusion criteria

Exclusion criteria: 1. Allergic to the investigational drug; 2. Schizophrenia and severe depression; 3. Myasthenia gravis; 4. Patients with respiratory diseases; 5. Patients with cardiovascular disease; 6. Patients with other serious systemic diseases; 7. Severe obesity, BMI=35.

Design outcomes

Primary

MeasureTime frame
Hemodynamic changes during induction of general anesthesia;Stress reaction during tracheal intubation;Emergence agitation;

Secondary

MeasureTime frame
Intubation-related complications;Perioperative related complications;

Countries

China

Contacts

Public ContactRenhu Li

Lu'an Hospital of Anhui Medical University

lirenhu2008@163.com+86 139 6624 1616

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026